KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBT Margin: 2011-2025

Historic EBT Margin for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to 15.60%.

  • Travere Therapeutics' EBT Margin rose 10278.00% to 15.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -20.32%, marking a year-over-year increase of 15108.00%. This contributed to the annual value of -137.45% for FY2024, which is 12151.00% up from last year.
  • Travere Therapeutics' EBT Margin amounted to 15.60% in Q3 2025, which was up 240.17% from -11.13% recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' EBT Margin registered a high of 15.60% during Q3 2025, and its lowest value of -739.75% during Q4 2021.
  • Over the past 3 years, Travere Therapeutics' median EBT Margin value was -128.55% (recorded in 2024), while the average stood at -157.84%.
  • As far as peak fluctuations go, Travere Therapeutics' EBT Margin plummeted by 50,027bps in 2021, and later surged by 44,808bps in 2022.
  • Travere Therapeutics' EBT Margin (Quarterly) stood at -739.75% in 2021, then surged by 44,808bps to -291.67% in 2022, then surged by 9,520bps to -196.47% in 2023, then soared by 11,579bps to -80.68% in 2024, then soared by 10,278bps to 15.60% in 2025.
  • Its EBT Margin stands at 15.60% for Q3 2025, versus -11.13% for Q2 2025 and -50.39% for Q1 2025.